Sarah Aebersold Sells 5,632 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,632 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72. Following the completion of the sale, the insider now directly owns 45,860 shares of the company’s stock, valued at $1,144,665.60. This trade represents a 10.94 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Performance

BioLife Solutions stock opened at $25.48 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a fifty day moving average price of $26.48 and a two-hundred day moving average price of $25.49. The company has a market cap of $1.20 billion, a PE ratio of -24.04 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period in the previous year, the business posted ($0.21) EPS. Research analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright boosted their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reissued a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, StockNews.com upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently made changes to their positions in BLFS. Invesco Ltd. lifted its holdings in shares of BioLife Solutions by 1.1% in the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock worth $84,097,000 after purchasing an additional 36,176 shares during the last quarter. Fred Alger Management LLC increased its position in BioLife Solutions by 1.0% in the fourth quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after buying an additional 16,274 shares during the period. State Street Corp lifted its stake in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock valued at $29,733,000 after acquiring an additional 377,111 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of BioLife Solutions by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock worth $23,028,000 after acquiring an additional 40,416 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.